5 active not recruiting, 5 recruiting, 2 completed, 2 terminated. 5 Phase 1, 5 Phase 2, 2 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Active not recruiting 2, Completed 2, Recruiting 1 |
| Phase 2 | 5 | Active not recruiting 2, Recruiting 1, Terminated 1, Unknown 1 |
| Early Phase 1 | 2 | Active not recruiting 1, Recruiting 1 |
Follow Stage IIIA Rectal Cancer AJCC v8: new trials by email Literature Review of Stage IIIA Rectal Cancer AJCC v8 trials Research Report on Stage IIIA Rectal Cancer AJCC v8
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3 Balstilimab, Biospecimen Collection, Botensilimab - Advanced Colon Adenocarcinoma, Advanced Colorectal Adenocarcinoma | Phase 2 | Recruiting | City of Hope Medical Center | 100 | 2026-07-01 | 2026-10-19 |
| Active Surveillance and Chemotherapy Before Surgery in Treating Participants With Stage II-III Rectal Cancer Chemotherapy, Patient Observation, Questionnaire Administration - Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8 | Early Phase 1 | Recruiting | M.D. Anderson Cancer Center | 120 | 2024-03-13 | 2026-05-20 |
| An Investigational Scan (64Cu-Labeled M5A Antibody) in Combination With SOC Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer Copper Cu 64 Anti-CEA Monoclonal Antibody M5A, Imaging Technique - Locally Advanced Rectal Carcinoma, Stage III Rectal Cancer AJCC v8 | Early Phase 1 | Active not recruiting | City of Hope Medical Center | 14 | 2022-08-31 | 2026-06-08 |
| Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer Biopsy, Biospecimen Collection, Electronic Health Record Review - Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8 | Recruiting | OHSU Knight Cancer Institute | 50 | 2021-09-03 | 2026-09-16 | |
| Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer Capecitabine, Fluorouracil, Intensity-Modulated Radiation Therapy - Locally Advanced Rectal Carcinoma, Rectal Adenocarcinoma | Phase 1 | Recruiting | Jonsson Comprehensive Cancer Center | 25 | 2021-02-11 | 2026-03-30 |
| LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer Abemaciclib, Cetuximab, ERK1/2 Inhibitor LY3214996 - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 46 | 2020-12-02 | 2026-10-05 |
| SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial CXCR1/2 Inhibitor SX-682, Nivolumab - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 51 | 2020-10-14 | 2026-07-20 |
| Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer Ipilimumab, Nivolumab, Regorafenib - Advanced Colon Adenocarcinoma, Metastatic Colon Adenocarcinoma | Phase 1 | Completed | City of Hope Medical Center | 39 | 2020-05-27 | 2026-01-28 |
| Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer Panitumumab, Quality-of-Life Assessment, Questionnaire Administration - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma | Phase 2 | Unknown | Academic and Community Cancer Research United | 12 | 2020-04-24 | 2024-05-21 |
| Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial Genetic Testing - Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma | Terminated | Academic and Community Cancer Research United | 199 | 2020-04-20 | 2025-08-29 | |
| TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer 3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, Trifluridine and Tipiracil Hydrochloride - Rectal Adenocarcinoma, Stage IIA Rectal Cancer AJCC v8 | Phase 1 | Completed | OHSU Knight Cancer Institute | 19 | 2019-12-11 | 2026-08-06 |
| Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer Savolitinib - Colorectal Carcinoma, Metastatic Colon Adenocarcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 5 | 2019-07-25 | 2023-10-17 |
| Financial Burden Assessment in Patients With Stage I-III Colon or Rectal Cancer Undergoing Treatment Quality-of-Life Assessment, Questionnaire Administration - Stage I Colon Cancer AJCC v8, Stage I Rectal Cancer AJCC v8 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 565 | 2018-06-11 | 2026-09-25 | |
| Evaluation of Quality of Life and Utilities Following Surgical Treatment of Stage I-IV Rectal Cancer Quality-of-Life Assessment, Questionnaire Administration - Rectal Adenocarcinoma, Stage I Rectal Cancer AJCC v8 | Recruiting | M.D. Anderson Cancer Center | 430 | 2014-05-16 | 2026-08-31 | |
| Circulating Tumor Cells in Patients With Locally Advanced Rectal Cancer Biospecimen Collection - Locally Advanced Rectal Adenocarcinoma, Metastatic Rectal Adenocarcinoma | Active not recruiting | M.D. Anderson Cancer Center | 341 | 2013-09-05 | 2026-09-18 |
Rectal Neoplasms (15) · Colonic Neoplasms (8) · Colorectal Neoplasms (5)
Digestive System Diseases (15) · Digestive System Neoplasms (15) · Gastrointestinal Diseases (15) · Gastrointestinal Neoplasms (15) · Intestinal Diseases (15) · Intestinal Neoplasms (15) · Neoplasms (15) · Neoplasms by Site (15) · Rectal Diseases (15) · Colorectal Neoplasms (10) · Colonic Diseases (8)
Nivolumab (2) · Radiotherapy, Intensity-Modulated (2) · Trifluridine (2) · regorafenib (2) · trifluridine tipiracil drug combination (2) · 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine (1) · Biopsy (1) · CTLA-4 Antigen (1) · Capecitabine (1) · Cetuximab (1) · Copper (1) · Drug Therapy (1) · Fluorouracil (1) · Genetic Testing (1) · Ipilimumab (1)
M.D. Anderson Cancer Center (5) · City of Hope Medical Center (3) · Academic and Community Cancer Research United (2) · OHSU Knight Cancer Institute (2) · ECOG-ACRIN Cancer Research Group (1) · Jonsson Comprehensive Cancer Center (1) · National Cancer Institute (NCI) (1)
United States (15)
John H Strickler (3) · Adel Kardosh, M.D.,Ph.D. (1) · Alisha Bent, MD (1) · Ann Raldow (1) · Charles D Lopez, MD, PhD (1) · Christine M Parseghian, MD (1) · George Chang (1) · George J Chang (1) · Jeffrey Y Wong (1) · Marwan G Fakih (1) · Pashtoon M Kasi (1) · Sheetal Kircher (1) · Yi-Qian N You (1)
PMID 36892833, PMID 38194233, PMID 39287948, PMID 39652198, PMID 41781240
P30CA015083 (2), P30CA033572 (2), K07CA133187 (1), R01CA187238 (1), U10CA180820 (1), UG1CA189828 (1), UM1CA186704 (1)